XML 55 R45.htm IDEA: XBRL DOCUMENT v3.19.2

Collaborations and Other Arrangements (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	$ 5,636.7	$ 5,585.0	$ 10,728.9	$ 10,548.8
R&D expense	1,402.2	1,271.0	2,632.7	2,378.5
U.S.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	3,252.5	3,242.3	6,143.3	6,037.9
Europe
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	928.2	941.0	1,828.5	1,834.8
Japan
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	653.2	640.4	1,196.9	1,177.2
Basaglar
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	290.7	201.8	542.1	367.8
Basaglar | U.S.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	232.2	156.5	430.3	283.2
Jardiance
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	231.9	147.2	435.5	298.2
Jardiance | U.S.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	142.6	85.6	267.8	180.6
Trajenta
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	153.9	141.7	285.9	282.8
Trajenta | U.S.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	64.5	56.8	111.8	110.9
Olumiant®
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	102.4	44.7	184.5	76.9
Olumiant® | U.S.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	$ 10.7	$ 1.7	17.1	$ 1.7
Milestone Payments, Development and Regulatory, Capitalized, Cumulative | Basaglar
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones (deferred) capitalized			(250.0)
Milestone Payments, Development and Regulatory, Capitalized, Cumulative | Jardiance
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones (deferred) capitalized			289.0
Milestone Payments, Development and Regulatory, Capitalized, Cumulative | Trajenta
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones (deferred) capitalized			$ 446.4
Royalty Agreement Terms | Olumiant®
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, rights and obligations, percentage			20.00%
Milestone Payments, Development and Regulatory, Capitalized (Deferred) | Olumiant® | U.S.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones (deferred) capitalized					$ 100.0
Milestone Payments, Development and Regulatory, Capitalized (Deferred) | Olumiant® | Europe
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones (deferred) capitalized						$ 65.0
Milestone Payments, Development and Regulatory, Capitalized (Deferred) | Olumiant® | Japan
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones (deferred) capitalized						15.0
Milestone Payments, Development and Regulatory, Expensed | Olumiant®
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
R&D expense					$ 20.0	$ 30.0	$ 55.0
Milestone Payments, Development and Regulatory | Olumiant®
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones (deferred) capitalized			$ 130.0
Milestone Payments, Development and Regulatory | Tanezumab
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones (deferred) capitalized			350.0
Milestone Payments, Sales-based | Olumiant®
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones (deferred) capitalized			150.0
Milestone Payments, Sales-based | Tanezumab
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestones (deferred) capitalized			$ 1,230.0
Research and Development Exp | Olumiant®
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, rights and obligations, percentage			30.00%

X

- Definition

Description of rights and obligations under the collaborative arrangements, including but not limited to - percent share in various revenues and costs, percent interest earned on related party notes.

+ References

No definition available.

+ Details

Name:	lly_CollaborativeArrangementRightsAndObligationsPercent
Namespace Prefix:	lly_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Terms or rights and obligations under collaborative arrangements.

+ References

No definition available.

+ Details

Name:	lly_CollaborativeArrangementRightsAndObligationsTerms
Namespace Prefix:	lly_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

+ Details

Name:	us-gaap_Revenues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	srt_StatementGeographicalAxis=country_US
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=country_JP
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=lly_BasaglarMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=lly_JardianceMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=lly_TrajentaBIMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=lly_OlumiantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredCumulativeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_RoyaltyAgreementTermsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryCapitalizedDeferredMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentandRegulatoryExpensedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsDevelopmentAndRegulatoryMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=lly_TanezumabMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=lly_MilestonePaymentsSalesBasedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: